Table 1. |
Stages of Chronic Kidney Disease |
Table 2. |
Major Features of Abnormalities in Mineral Metabolism in Kidney Failure |
Table 3. |
Factors Affecting the Level of Serum Phosphorus in CKD |
Table 4. |
Biological Consequences of Vitamin D Deficiency |
Table 5. |
Possible Reasons for Variations in Bone Disease Among Patients with Chronic Kidney Disease |
Table 6. |
Factors That May Predispose to Soft-Tissue Calcification in Stages 4 and 5 CKD |
Table 7. |
Steps Used to Develop the Bone Disease Guidelines |
Table 8. |
Summary of Article Retrievals |
Table 9. |
Evidence Base for Evidence Reports |
Table 10. |
Rating of Methodological Quality |
Table 11. |
Rating of Applicability |
Table 12. |
Example of a Study Quality Overview Table |
Table 13. |
Grading Rationale Statements |
Table 14. |
Frequency of Measurement of PTH and Calcium/Phosphorus by Stage of CKD |
Table 15. |
Target Range of Intact Plasma PTH by Stage of CKD |
Table 16. |
Factors Prevalent in CKD Patients Which May Influence the Type of Osteodystrophy Lesion |
Table 17. |
Non–CKD-Related Factor Which May Affect Bone Metabolism in CKD Patients |
Table 18. |
Pathologies Identified by Bone Biopsy Measures |
Table 19. |
Side Effects Associated with a Phosphorus-Restricted Diet and Their Rate of Occurrence |
Table 20. |
Phosphorus Content of Protein-Containing Foods |
Table 21. |
Steps To Calculate the Initial Binder Prescription |
Table 22. |
Phosphorus-Binding Compounds |
Table 23. |
Adequate and Upper Intake Levels of Calcium for Healthy People by Age |
Table 24. |
Calcium Content of Common Calcium-Based Binders |
Table 25. |
Factorial Analysis for Determining Calcium Requirements in Adults Aged 19-30 Years |
Table 26. |
Recommended Supplementation for Vitamin D Deficiency/Insufficiency in Patients with CKD Stages 3 and 4 |
Table 27. |
Serum Levels of PTH, Calcium and Phosphate Required for Initiation of Oral Vitamin D Sterol Therapy, and Recommended Initial Doses in Patients with Stages 3 and 4 CKD |
Table 28. |
Recommended Initial Dosing for Vitamin D Sterols by Serum Levels of Intact PTH, Calcium, Phosphorus, and Ca-P Product |
Table 29. |
Effect of Dialysis Membranes on the Development of Clinical or Radiographic Symptoms of β2-Microglobulin Amyloidosis |
Table 30. |
Summary of the Results of the Effect of Different Dialysis Membranes on β2-Microglobulin Serum Levels |
Table 31. |
Aluminum-Related Disorders: Features, Causes and Considerations for Therapy |
Table 32. |
Frequency for Measurement of Serum Levels of Total CO2 |
Table 33. |
Frequency of Measurement of Calcium, Phosphorus, PTH and Total CO2 after Kidney Transplantation |
Table 34. |
Commercially Available Preparations for Phosphate Supplementation |